{"id":"https://openalex.org/W2903379674","doi":"https://doi.org/10.1016/j.jtho.2018.11.028","title":"Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation","display_name":"Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation","publication_year":2018,"publication_date":"2018-12-04","ids":{"openalex":"https://openalex.org/W2903379674","doi":"https://doi.org/10.1016/j.jtho.2018.11.028","mag":"2903379674","pmid":"https://pubmed.ncbi.nlm.nih.gov/30529597"},"language":"en","primary_location":{"id":"doi:10.1016/j.jtho.2018.11.028","doi":"https://doi.org/10.1016/j.jtho.2018.11.028","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jtho.2018.11.028","pdf_url":null,"source":{"id":"https://openalex.org/S90745127","display_name":"Journal of Thoracic Oncology","issn_l":"1556-0864","issn":["1556-0864","1556-1380"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Thoracic Oncology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://doi.org/10.1016/j.jtho.2018.11.028","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5055074037","display_name":"James Chih\u2010Hsin Yang","orcid":"https://orcid.org/0000-0002-5586-5138","observed_orcids":["https://orcid.org/0000-0002-5586-5138"]},"institutions":[{"id":"https://openalex.org/I4210131804","display_name":"National Taiwan University Hospital","ror":"https://ror.org/03nteze27","country_code":"TW","type":"healthcare","lineage":["https://openalex.org/I4210131804"]}],"countries":["TW"],"is_corresponding":true,"raw_author_name":"James Chih-Hsin Yang","raw_affiliation_strings":["National Taiwan University Hospital and National Taiwan University Cancer Center, Taiwan, Republic of China. Electronic address: chihyang@ntu.edu.tw","National Taiwan University Hospital and National Taiwan University Cancer Center, Taiwan, Republic of China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Taiwan University Hospital and National Taiwan University Cancer Center, Taiwan, Republic of China. Electronic address: chihyang@ntu.edu.tw","institution_ids":["https://openalex.org/I4210131804"]},{"raw_affiliation_string":"National Taiwan University Hospital and National Taiwan University Cancer Center, Taiwan, Republic of China","institution_ids":["https://openalex.org/I4210131804"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025836672","display_name":"Shirish M. Gadgeel","orcid":"https://orcid.org/0000-0001-5240-3811","observed_orcids":["https://orcid.org/0000-0001-5240-3811"]},"institutions":[{"id":"https://openalex.org/I185443292","display_name":"Wayne State University","ror":"https://ror.org/01070mq45","country_code":"US","type":"education","lineage":["https://openalex.org/I185443292"]},{"id":"https://openalex.org/I4210090317","display_name":"The Barbara Ann Karmanos Cancer Institute","ror":"https://ror.org/00ee40h97","country_code":"US","type":"facility","lineage":["https://openalex.org/I2800590384","https://openalex.org/I4210090317"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shirish M. Gadgeel","raw_affiliation_strings":["Karmanos Cancer Institute and Wayne State University, Detroit, Michigan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Karmanos Cancer Institute and Wayne State University, Detroit, Michigan","institution_ids":["https://openalex.org/I185443292","https://openalex.org/I4210090317"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075333926","display_name":"Lecia Van Dam Sequist","orcid":"https://orcid.org/0000-0002-8965-6991","observed_orcids":["https://orcid.org/0000-0002-8965-6991"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lecia VanDam Sequist","raw_affiliation_strings":["Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110350816","display_name":"Chien-Liang Wu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2802753785","display_name":"Mackay Memorial Hospital","ror":"https://ror.org/015b6az38","country_code":"TW","type":"healthcare","lineage":["https://openalex.org/I2802753785"]}],"countries":["TW"],"is_corresponding":false,"raw_author_name":"Chien-Liang Wu","raw_affiliation_strings":["Mackay Memorial Hospital, Taiwan, Republic of China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mackay Memorial Hospital, Taiwan, Republic of China","institution_ids":["https://openalex.org/I2802753785"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008790176","display_name":"Vassiliki A. Papadimitrakopoulou","orcid":"https://orcid.org/0000-0003-3172-1399","observed_orcids":["https://orcid.org/0000-0003-3172-1399"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Vassiliki A. Papadimitrakopoulou","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, Texas","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028823803","display_name":"Wu\u2010Chou Su","orcid":"https://orcid.org/0000-0003-2953-4105","observed_orcids":["https://orcid.org/0000-0003-2953-4105"]},"institutions":[{"id":"https://openalex.org/I4210158999","display_name":"National Cheng Kung University Hospital","ror":"https://ror.org/04zx3rq17","country_code":"TW","type":"healthcare","lineage":["https://openalex.org/I4210158999"]}],"countries":["TW"],"is_corresponding":false,"raw_author_name":"Wu-Chou Su","raw_affiliation_strings":["National Cheng Kung University Hospital, Tainan City, Taiwan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Cheng Kung University Hospital, Tainan City, Taiwan","institution_ids":["https://openalex.org/I4210158999"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020305937","display_name":"Joseph Fiore","orcid":"https://orcid.org/0000-0003-0591-1877","observed_orcids":["https://orcid.org/0000-0003-0591-1877"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joseph Fiore","raw_affiliation_strings":["Merck & Co., Inc., Kenilworth, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., Kenilworth, New Jersey","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016466602","display_name":"Sanatan Saraf","orcid":"https://orcid.org/0009-0004-3183-6350","observed_orcids":["https://orcid.org/0009-0004-3183-6350"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sanatan Saraf","raw_affiliation_strings":["Merck & Co., Inc., Kenilworth, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., Kenilworth, New Jersey","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064784334","display_name":"Harry Raftopoulos","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Harry Raftopoulos","raw_affiliation_strings":["Merck & Co., Inc., Kenilworth, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., Kenilworth, New Jersey","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5070570779","display_name":"Amita Patnaik","orcid":"https://orcid.org/0000-0002-4144-2193","observed_orcids":["https://orcid.org/0000-0002-4144-2193"]},"institutions":[{"id":"https://openalex.org/I4210119066","display_name":"South Texas Accelerated Research Therapeutics","ror":"https://ror.org/01scs7915","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210119066"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amita Patnaik","raw_affiliation_strings":["South Texas Accelerated Research Therapeutics, San Antonio, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"South Texas Accelerated Research Therapeutics, San Antonio, Texas","institution_ids":["https://openalex.org/I4210119066"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":10,"corresponding_author_ids":["https://openalex.org/A5055074037"],"corresponding_institution_ids":["https://openalex.org/I4210131804"],"apc_list":{"value":4100,"currency":"USD","value_usd":4100},"apc_paid":null,"fwci":12.0179,"has_fulltext":false,"cited_by_count":181,"citation_normalized_percentile":{"value":0.99150896,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":99,"max":100},"biblio":{"volume":"14","issue":"3","first_page":"553","last_page":"559"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0015999999595806003,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":1.0},{"id":"https://openalex.org/keywords/erlotinib","display_name":"erlotinib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/gefitinib","display_name":"gefitinib","score":1.0},{"id":"https://openalex.org/keywords/egfr-mutant-non-small-cell-lung-cancer","display_name":"EGFR-mutant non-small cell lung cancer","score":0.9210000038146973},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.7089999914169312},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.5770000219345093},{"id":"https://openalex.org/keywords/anti-egfr-therapy","display_name":"anti-EGFR therapy","score":0.8539999723434448},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.6140000224113464},{"id":"https://openalex.org/keywords/pd-1-pd-l1-blockade","display_name":"PD-1/PD-L1 blockade","score":0.7390000224113464},{"id":"https://openalex.org/keywords/hepatotoxicity","display_name":"hepatotoxicity","score":0.7360000014305115},{"id":"https://openalex.org/keywords/treatment-related-toxicity","display_name":"treatment toxicity","score":0.5109999775886536},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.8119999766349792},{"id":"https://openalex.org/keywords/pd-l1-expression","display_name":"PD-L1 expression","score":0.621999979019165}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9400226473808289},{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.939368724822998},{"id":"https://openalex.org/C2780580887","wikidata":"https://www.wikidata.org/wiki/Q417824","display_name":"Gefitinib","level":4,"score":0.9014047384262085},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.7211456298828125},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6272127628326416},{"id":"https://openalex.org/C2994076244","wikidata":"https://www.wikidata.org/wiki/Q179661","display_name":"First line therapy","level":2,"score":0.4802561104297638},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.47393089532852173},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.24656400084495544},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.11244940757751465},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.07516083121299744}],"mesh":[{"descriptor_ui":"D000069347","descriptor_name":"Erlotinib Hydrochloride","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000077156","descriptor_name":"Gefitinib","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005500","descriptor_name":"Follow-Up Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009154","descriptor_name":"Mutation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D011379","descriptor_name":"Prognosis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015331","descriptor_name":"Cohort Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015996","descriptor_name":"Survival Rate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1016/j.jtho.2018.11.028","doi":"https://doi.org/10.1016/j.jtho.2018.11.028","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jtho.2018.11.028","pdf_url":null,"source":{"id":"https://openalex.org/S90745127","display_name":"Journal of Thoracic Oncology","issn_l":"1556-0864","issn":["1556-0864","1556-1380"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Thoracic Oncology","raw_type":"journal-article"},{"id":"pmid:30529597","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/30529597","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","raw_type":"Clinical Trial, Phase I"}],"best_oa_location":{"id":"doi:10.1016/j.jtho.2018.11.028","doi":"https://doi.org/10.1016/j.jtho.2018.11.028","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jtho.2018.11.028","pdf_url":null,"source":{"id":"https://openalex.org/S90745127","display_name":"Journal of Thoracic Oncology","issn_l":"1556-0864","issn":["1556-0864","1556-1380"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Thoracic Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"score":0.8500000238418579,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320306091","display_name":"American Association for Cancer Research","ror":"https://ror.org/02fnpv153"},{"id":"https://openalex.org/F4320307115","display_name":"Bristol-Myers Squibb","ror":"https://ror.org/00gtmwv55"},{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"},{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"},{"id":"https://openalex.org/F4320307771","display_name":"Bayer","ror":"https://ror.org/04hmn8g73"},{"id":"https://openalex.org/F4320307776","display_name":"Merck","ror":"https://ror.org/02891sr49"},{"id":"https://openalex.org/F4320307778","display_name":"Novartis","ror":"https://ror.org/02f9zrr09"},{"id":"https://openalex.org/F4320307779","display_name":"Roche","ror":"https://ror.org/00by1q217"},{"id":"https://openalex.org/F4320308129","display_name":"Cancer Prevention and Research Institute of Texas","ror":"https://ror.org/0003xa228"},{"id":"https://openalex.org/F4320309021","display_name":"Ariad Pharmaceuticals","ror":"https://ror.org/01dwtyk53"},{"id":"https://openalex.org/F4320309086","display_name":"Celgene","ror":"https://ror.org/0527yg379"},{"id":"https://openalex.org/F4320310441","display_name":"Boehringer Ingelheim","ror":"https://ror.org/00q32j219"},{"id":"https://openalex.org/F4320312773","display_name":"University of South Alabama","ror":"https://ror.org/01s7b5y08"},{"id":"https://openalex.org/F4320322789","display_name":"Mount Sylvia Diatomite","ror":"https://ror.org/011k8d702"},{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320332193","display_name":"Genentech","ror":"https://ror.org/04gndp242"},{"id":"https://openalex.org/F4320332521","display_name":"University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07"},{"id":"https://openalex.org/F4320332932","display_name":"Merck Sharp and Dohme","ror":"https://ror.org/004nn4n27"},{"id":"https://openalex.org/F4320335359","display_name":"Pharmaceuticals Bayer","ror":null},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":14,"referenced_works":["https://openalex.org/W1982488143","https://openalex.org/W2071865120","https://openalex.org/W2111662961","https://openalex.org/W2123918574","https://openalex.org/W2166084034","https://openalex.org/W2465300868","https://openalex.org/W2527905628","https://openalex.org/W2560717039","https://openalex.org/W2594042408","https://openalex.org/W2594980227","https://openalex.org/W2770828094","https://openalex.org/W2784548224","https://openalex.org/W2803642760","https://openalex.org/W2806388842"],"related_works":["https://openalex.org/W2803642760","https://openalex.org/W2237385549","https://openalex.org/W3100771618","https://openalex.org/W110737512","https://openalex.org/W4323033684","https://openalex.org/W2898336477","https://openalex.org/W2904019899","https://openalex.org/W3009161381","https://openalex.org/W2212248724","https://openalex.org/W4233387073"],"abstract_inverted_index":null,"counts_by_year":[{"year":2026,"cited_by_count":12},{"year":2025,"cited_by_count":22},{"year":2024,"cited_by_count":19},{"year":2023,"cited_by_count":27},{"year":2022,"cited_by_count":36},{"year":2021,"cited_by_count":34},{"year":2020,"cited_by_count":22},{"year":2019,"cited_by_count":8}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2018-12-11T00:00:00"}